论文部分内容阅读
目的:评价国产培美曲塞联合国产洛铂一线治疗中晚期肺腺癌的近期疗效和毒副作用。方法:对40例经病理确诊为中晚期肺腺癌患者,国产培美曲塞500mg/m2,静脉滴入,d1;国产洛铂30mg/m2,静脉滴入,d1,21d为1个周期,并口服地塞米松、叶酸和肌肉注射维生素B12以减轻毒副作用。按照1981年WHO实体瘤疗效评定标准评价有效率、无进展生存期和毒副作用。结果:40例患者中,完全缓解2例(5.0%),部分缓解16例(40.0%),稳定13例(32.5%),疾病进展9例(22.5%),总有效率为45.0%(18/40),疾病控制率为77.5%(31/40),中位无进展生存期5.6个月。ⅢB和Ⅳ期患者之间的疗效没有明显差异。与药物相关的不良反应主要为Ⅰ/Ⅱ度骨髓抑制和胃肠道反应。Ⅲ/Ⅳ度毒性作用发生率仅2例(5.0%),无脱发、肾毒性及神经毒性发生。结论:国产培美曲塞联合国产洛铂一线治疗中晚期肺腺癌具有较好的疗效和安全性。
OBJECTIVE: To evaluate the short-term curative effect and side effects of domestic pemetrexed combined with losartan in the treatment of advanced lung adenocarcinoma. Methods: Forty patients with pathologically diagnosed advanced lung adenocarcinoma were treated with pemetrexed 500mg / m2 intravenously, d1; domestic Losoplatin 30mg / m2, intravenously, d1 and 21d for one cycle, And oral dexamethasone, folic acid and intramuscular injection of vitamin B12 to reduce side effects. Efficacy, progression-free survival and adverse effects were evaluated according to the 1981 WHO Evaluation of Efficacy of Solid Tumors. Results: In 40 patients, complete remission was achieved in 2 cases (5.0%), partial remission in 16 cases (40.0%), stable in 13 cases (32.5%), disease progression in 9 cases (22.5%), and total effective rate was 45.0% / 40), disease control rate was 77.5% (31/40), median progression-free survival 5.6 months. There was no significant difference in the efficacy between stage IIB and stage IV patients. Drug-related adverse reactions mainly Ⅰ / Ⅱ degree bone marrow suppression and gastrointestinal reactions. Ⅲ / Ⅳ degree of toxicity of the incidence of only 2 cases (5.0%), no hair loss, nephrotoxicity and neurotoxicity. Conclusion: The domestic Pemetrexed combined with the first-line treatment of lobaplatin in advanced lung adenocarcinoma has good efficacy and safety.